Comparison of Recovery Quality Following Medetomidine versus Xylazine Balanced Isoflurane Anaesthesia in Horses: A Retrospective Analysis

Abstract

Simple Summary Recovery from general anaesthesia poses the most critical phase of equine anaesthesia and is the main cause for the relatively high anaesthetic mortality rate compared to other species. It is, therefore, essential to identify anaesthetic protocols that promote safe recoveries. This retrospective study compared the quality of 470 recoveries following general anaesthesia with the anaesthetic gas isoflurane combined with a constant rate infusion of two different alpha-2 adrenergic agonists (xylazine or medetomidine). On the basis of video recordings, recovery quality was scored by two observers unaware of animal details, procedure, or drugs used. Additionally, factors that may affect recovery (e.g., breed, age, procedure, duration of anaesthesia, and intraoperative complications) were taken into consideration. Horses needing higher doses of xylazine to sedate prior to anaesthesia, the intraoperative use of tetrastarch for cardiovascular support, and the use of salbutamol to improve inadequate blood oxygenation during general anaesthesia were related to poorer recovery scores. Whilst recoveries of horses treated with medetomidine took significantly longer compared to xylazine, the attempts to stand and the overall quality of recovery were similar for both groups, indicating that both anaesthetic protocols promote similarly safe recoveries. Abstract Medetomidine partial intravenous anaesthesia (PIVA) has not been compared to xylazine PIVA regarding quality of recovery. This clinical retrospective study compared recoveries following isoflurane anaesthesia balanced with medetomidine or xylazine. The following standard protocol was used: sedation with 7 µg·kg−1 medetomidine or 1.1 mg·kg−1 xylazine, anaesthesia induction with ketamine/diazepam, maintenance with isoflurane and 3.5 µg·kg−1·h−1 medetomidine or 0.7 mg·kg−1·h−1 xylazine, and sedation after anaesthesia with 2 µg·kg−1 medetomidine or 0.3 mg·kg−1 xylazine. Recovery was timed and, using video recordings, numerically scored by two blinded observers. Influence of demographics, procedure, peri-anaesthetic drugs, and intraoperative complications (hypotension, hypoxemia, and tachycardia) on recovery were analysed using regression analysis (p < 0.05). A total of 470 recoveries (medetomidine 279, xylazine 191) were finally included. Following medetomidine, recoveries were significantly longer (median (interquartile range): 57 (43–71) min) than xylazine (43 (32–59) min) (p < 0.001). However, the number of attempts to stand was similar (medetomidine and xylazine: 2 (1–3)). Poorer scores were seen with increased pre-anaesthetic dose of xylazine, intraoperative tetrastarch, or salbutamol. However, use of medetomidine or xylazine did not influence recovery score, concluding that, following medetomidine–isoflurane PIVA, recovery is longer, but of similar quality compared to xylazine.